360biolabs' key role in cancer research

Angus Morgan

28 July, 2016

Contract research organisation 360biolabs, a Burnet Institute joint initiative, is set to play a key role in the development of a novel in vitro diagnostic test for metastatic cancer.

In collaboration with Chemocopeia, Innoviron and CSIRO, 360biolabs has been awarded a Cooperative Research Centres Projects (CRC-P) grant administered by AusIndustry, a division of the Department of Industry, Innovation and Science.

The CRC Programme aims to foster high quality research to solve industry-identified problems through industry-led and outcome-focused collaborative research partnerships between industry entities and research organisations.

360biolabs CEO Dr Simon Tucker said his team is humbled to receive one of the first CRC-P grants and looking forward to working closely with colleagues in the CSIRO and Chemocopeia in this significant research.

“360 bioloabs are going to use the antibodies that are owned by Chemocopeia and prepared by the CSIRO to develop a new diagnostic assay and validate that assay for clinical use in support of clinical trials,” Dr Tucker said.

“Markers for the progression of metastatic disease are urgently needed, both for the purpose of directing therapy and also to ensure that the patients and their physicians are informed about the state of the disease.

“At the moment, although there are a number of investigational ones, there are no easy, relatively simple blood-borne markers.

“This particular marker shows a lot of promise, but obviously has to be subjected to clinical trials.”

Formed in 2015 in a merger between Burnet’s Immuno Monitoring Facility (IMF) and Innoviron Pty Ltd, 360biolabs offers quality-assured immunology and virology laboratory services, supporting clinical trials aimed at developing therapeutics, vaccines and diagnostics.

To find out more about 360biolabs, visit

Contact Details

For more information in relation to this news article, please contact:

Burnet Institute




Subscribe to News

Subscribe to receive our latest news: